US Stock MarketDetailed Quotes
THAR Tharimmune
- 2.560
- -0.050-1.92%
Close Nov 22 16:00 ET
3.80MMarket Cap0.04P/E (TTM)
2.702High2.460Low106.28KVolume2.670Open2.610Pre Close278.78KTurnover7.28%Turnover RatioLossP/E (Static)1.49MShares71.85052wk High1.26P/B3.74MFloat Cap1.83552wk Low--Dividend TTM1.46MShs Float1590.000Historical High--Div YieldTTM9.27%Amplitude1.835Historical Low2.623Avg Price1Lot Size
Tharimmune Stock Forum
Sign in to post a comment
$Tharimmune (THAR.US)$
Tharimmune Presents Positive Clinical Data at AASLD the Liver Meeting(R) to Support TH104 for Chronic Pruritus in Chronic Liver Disease
Tharimmune (NASDAQ:THAR) presented Phase 1 clinical data for TH104 at AASLD The Liver Meeting 2024. The trial evaluated TH104 transmucosal buccal film in patients with chronic liver disease (CLD) for chronic pruritus treatment.
The study showed significant correlation between blood levels and symptom relief, with a correlation coeff...
Tharimmune Presents Positive Clinical Data at AASLD the Liver Meeting(R) to Support TH104 for Chronic Pruritus in Chronic Liver Disease
Tharimmune (NASDAQ:THAR) presented Phase 1 clinical data for TH104 at AASLD The Liver Meeting 2024. The trial evaluated TH104 transmucosal buccal film in patients with chronic liver disease (CLD) for chronic pruritus treatment.
The study showed significant correlation between blood levels and symptom relief, with a correlation coeff...
1
4
$Tharimmune (THAR.US)$ No News, why is pumping ? Manipulation again ??
1
1
$Tharimmune (THAR.US)$
Tharimmune Granted European Patent for Delivery of Optimized Molecularly Targeted Therapeutics
Tharimmune (NASDAQ:THAR) has been granted a European patent for biodegradable polymeric nanoparticles designed to deliver therapeutic antibodies and peptides. The technology aims to enhance drug delivery by improving stability and reducing systemic side effects, particularly in cancer therapies. The nanoparticles feature tunable size, non-toxic profiles, and extended drug hal...
Tharimmune Granted European Patent for Delivery of Optimized Molecularly Targeted Therapeutics
Tharimmune (NASDAQ:THAR) has been granted a European patent for biodegradable polymeric nanoparticles designed to deliver therapeutic antibodies and peptides. The technology aims to enhance drug delivery by improving stability and reducing systemic side effects, particularly in cancer therapies. The nanoparticles feature tunable size, non-toxic profiles, and extended drug hal...
$Tharimmune (THAR.US)$ Technically we are all losers! And MM’s Helped SS’s to win! Hehehe! But the moment you been waiting for in ( Todays edition of Just how corrupt are they ) Hehehe @Jaguar8 You are the closest with a vote of 50%! Hehehe! 56.92% Was sent off to hold the price down and save shorty! Grrrr! Hehehe! I will keep this 100% unbiased and let Y’all see the numbers yourself! Hehehe
5
9
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
No comment yet
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
HailTheApocalypse : welp if ya bought in, congrats
Jaguar8 OP HailTheApocalypse : Nope didn’t buy
HailTheApocalypse Jaguar8 OP : I'm sorry
Jaguar8 OP HailTheApocalypse : Didn’t run actually